- Drug Pipelines
- August 2020
- 384 Pages
Global
From €1919EUR$2,000USD£1,648GBP
- Report
- June 2022
- 96 Pages
Global
From €3500EUR$3,908USD£3,112GBP
- Report
- April 2022
- 106 Pages
Global
From €3500EUR$3,908USD£3,112GBP
- Report
- February 2022
- 92 Pages
Global
From €3200EUR$3,573USD£2,845GBP
- Report
- July 2021
- 96 Pages
Global
From €3200EUR$3,573USD£2,845GBP
- Report
- April 2022
- 413 Pages
Global
From €2398EUR$2,500USD£2,060GBP
- Report
- April 2021
- 100 Pages
Global
From €1919EUR$2,000USD£1,648GBP
- Drug Pipelines
- February 2020
- 62 Pages
Global
From €3358EUR$3,500USD£2,884GBP
- Report
- June 2023
- 132 Pages
Global
From €911EUR$950USD£783GBP
- Report
- October 2021
- 288 Pages
Global
From €3561EUR$3,712USD£3,059GBP
- Report
- September 2023
- 200 Pages
Global
From €2877EUR$2,999USD£2,471GBP
The Osteoarthritis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Osteoarthritis is a degenerative joint disease that affects millions of people worldwide. It is characterized by the breakdown of cartilage in the joints, leading to pain, stiffness, and decreased mobility. Treatment for osteoarthritis typically involves a combination of lifestyle changes, physical therapy, and medications. Common medications used to treat osteoarthritis include non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, and disease-modifying antirheumatic drugs (DMARDs).
The Osteoarthritis Drug market is highly competitive, with a variety of companies offering products to treat the condition. Some of the major players in the market include Pfizer, Merck, Novartis, AbbVie, and Johnson & Johnson. Other companies such as Amgen, Eli Lilly, and Bristol-Myers Squibb also offer products for the treatment of osteoarthritis. Show Less Read more
